Document Detail


A review of the efficacy and safety of oral antidiabetic drugs.
MedLine Citation:
PMID:  23241069     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Additional oral antidiabetic agents to metformin, sulfonylureas (SU) and thiazolidinediones (TZD) are approved for the treatment of type 2 diabetes.
AREAS COVERED: The efficacy and safety of metformin, SUs, TZDs, dipeptidyl peptidase-IV (DPP-4) inhibitors, meglitinide analogs, α-glucosidase inhibitors (AGIs), bile-acid sequestrants (BAS) and bromocriptine will be reviewed.
EXPERT OPINION: Several new oral agents have been approved for type 2 diabetes management in recent years. It is important to understand the efficacy and safety of these medications in addition to the older agents to best maximize oral drug therapy for diabetes. Of the recently introduced oral hypoglycemic/antihyperglycemic agents, the DPP-4 inhibitors are moderately efficacious compared with mainstay treatment with metformin with a low side-effect profile and have good efficacy in combination with other oral agents and insulin. They are a recommended alternative when metformin use is limited by gastrointestinal (GI) side effects or when SU treatment results in significant hypoglycemia or weight gain. Meglitinide analogs are limited by their frequent dosing, expense and hypoglycemia (repaglinide > nateglinide), while AGIs are also limited by their dosing schedule and GI side-effect profile. BAS and bromocriptine have the lowest efficacy with regard to HbA(1c) reduction, also are plagued by GI adverse reactions, but have a low risk of hypoglycemia.
Authors:
Stephanie Aleskow Stein; Elizabeth Mary Lamos; Stephen N Davis
Related Documents :
24379269 - The role of peroxisome proliferator-activated receptors γ (pparγ) in obesity and insu...
23386729 - Treatment quality indicators predict short-term outcomes in patients with diabetes: a p...
23580229 - Omitting follow-up food after initial hypoglycaemic treatment does not increase the lik...
23711019 - Diabetes attitudes, wishes and needs second study (dawn2™): cross-national benchmarki...
23183559 - Diabetes-related lower-extremity amputation incidence and risk factors: a prospective s...
23418939 - Self management of type 2 diabetes by maltese immigrants in australia: can community ph...
6761199 - Regulation of serum potassium during insulin-induced hypoglycemia.
12850279 - Liver-specific igf-i gene deficient mice exhibit accelerated diabetes in response to st...
10590399 - Role of reactive oxygen species (ros) in the diabetes-induced anomalies in rat embryos ...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-12-14
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  12     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-20     Completed Date:  2013-10-31     Revised Date:  2014-10-29    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  153-75     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Diabetes Mellitus, Type 2 / blood,  drug therapy*,  epidemiology
Humans
Hypoglycemia / blood,  chemically induced
Hypoglycemic Agents / administration & dosage*,  adverse effects*
Metformin / administration & dosage,  adverse effects
Treatment Outcome
Grant Support
ID/Acronym/Agency:
M01 RR000095/RR/NCRR NIH HHS; P01 HL056693/HL/NHLBI NIH HHS; R01 DK069803/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 9100L32L2N/Metformin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sulfocoumarins (1,2-benzoxathiine 2,2-dioxides): a class of potent and isoform-selective inhibitors ...
Next Document:  Excision of the Deep Branch of the Lateral Palmar Nerve of Horses to Resolve Lameness Caused by Prox...